Brain stem cell injection aims to restore movement in Parkinson's

NCT ID NCT07212088

Not yet recruiting Disease control Sponsor: iCamuno Biotherapeutics Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial tests a single injection of lab-grown dopamine-producing cells into the brains of 12 people with advanced Parkinson's disease. The goal is to see if the procedure is safe and if it can improve motor function and quality of life. Participants must be between 55 and 75 years old, have had Parkinson's for over 5 years, and experience daily 'off' periods despite medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ALC01 therapy (iPSC-derived dopamine progenitor cells)
What this could lead to: If successful, this could point toward a cell-based treatment that restores dopamine function and improves motor symptoms in Parkinson's disease.
What could go wrong: This is a very early Phase 1 trial with only 12 participants, so safety and feasibility are the main focus. The procedure involves brain surgery, which carries risks like bleeding or infection, and the cells may not survive or work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Locations

Second Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.